Pliant Therapeutics to Participate in Upcoming Investor Conferences
25 7월 2023 - 9:00PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biotechnology company focused on discovering and developing novel
therapeutics for the treatment of fibrosis, today announced
participation in the following August investor conferences.
- BTIG
Virtual Biotechnology Conference 2023 Members of
senior management will meet with investors on Monday, August
7th.
- Canaccord Genuity
43rd Annual Growth Conference Bernard
Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer
and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer, will
participate in a fireside chat on Thursday, August 10th at 10:00 am
Eastern Time.
Interested parties may access the live webcast of
the Canaccord Genuity fireside chat by visiting the Investor
Relations’ Events & Presentation page of Pliant’s website. The
webcast replay will be archived on the Pliant website for 30 days
following the conclusion of the event.
About Pliant Therapeutics,
Inc.
Pliant Therapeutics is a clinical stage
biopharmaceutical company focused on discovering and developing
novel therapies for the treatment of fibrosis. Pliant's lead
product candidate, bexotegrast (PLN-74809), is an oral small
molecule dual selective inhibitor of αvß6 and αvß1 integrins that
is in development in the lead indications for the treatment of
idiopathic pulmonary fibrosis, or IPF, and primary sclerosing
cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant is
currently planning a Phase 2b trial of bexotegrast in IPF. Pliant
has also developed PLN-1474, a small molecule, selective inhibitor
of αvß1 for the treatment of nonalcoholic steatohepatitis, or NASH
with liver fibrosis. Pliant is initiating a Phase 1 study for its
third clinical program, PLN-101095, a small molecule,
dual-selective inhibitor of αvß8 and αvß1 integrins, that is being
developed for the treatment of solid tumors. In addition to
clinical stage programs, Pliant currently has a preclinical program
targeting muscular dystrophies. For additional information, please
visit: www.PliantRx.com. Follow us on social
media: Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor
Relations and Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Pliant Therapeutics (NASDAQ:PLRX)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024